<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1163" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1163/" /><meta name="ncbi_pagename" content="SCN9A-Related Inherited Erythromelalgia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>SCN9A-Related Inherited Erythromelalgia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="SCN9A-Related Inherited Erythromelalgia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/08/15" /><meta name="citation_author" content="Fuki M Hisama" /><meta name="citation_author" content="Sulayman D Dib-Hajj" /><meta name="citation_author" content="Stephen G Waxman" /><meta name="citation_pmid" content="20301342" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1163/" /><meta name="citation_keywords" content="Sodium channel protein type 9 subunit alpha" /><meta name="citation_keywords" content="SCN9A" /><meta name="citation_keywords" content="SCN9A-Related Inherited Erythromelalgia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="SCN9A-Related Inherited Erythromelalgia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Fuki M Hisama" /><meta name="DC.Contributor" content="Sulayman D Dib-Hajj" /><meta name="DC.Contributor" content="Stephen G Waxman" /><meta name="DC.Date" content="2013/08/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1163/" /><meta name="description" content="SCN9A-related inherited erythromelalgia (SCN9A-related IEM) is characterized by recurrent attacks of bilateral and symmetric intense pain, redness, warmth, and swelling involving the feet and, less frequently, the hands. SCN9A-related IEM is not associated with an organic disease. Manifestations may vary within a family. Onset is usually in childhood or adolescence but has been recognized in infants and adults. At onset, episodes are triggered by warmth; other precipitating factors include: exercise, tight shoes, wearing socks, alcohol, spicy foods, and other vasodilating agents. In advanced disease, symptoms may occur many times a day or become constant. Some individuals have allodynia (pain evoked by a normally innocuous stimulus) and hyperalgesia (increased sensitivity to a painful stimulus). Episodes may be disabling, interfere with sleep, and severely limit normal activities such as walking, participation in sports, wearing socks and shoes, and attending school or going to work." /><meta name="og:title" content="SCN9A-Related Inherited Erythromelalgia" /><meta name="og:type" content="book" /><meta name="og:description" content="SCN9A-related inherited erythromelalgia (SCN9A-related IEM) is characterized by recurrent attacks of bilateral and symmetric intense pain, redness, warmth, and swelling involving the feet and, less frequently, the hands. SCN9A-related IEM is not associated with an organic disease. Manifestations may vary within a family. Onset is usually in childhood or adolescence but has been recognized in infants and adults. At onset, episodes are triggered by warmth; other precipitating factors include: exercise, tight shoes, wearing socks, alcohol, spicy foods, and other vasodilating agents. In advanced disease, symptoms may occur many times a day or become constant. Some individuals have allodynia (pain evoked by a normally innocuous stimulus) and hyperalgesia (increased sensitivity to a painful stimulus). Episodes may be disabling, interfere with sleep, and severely limit normal activities such as walking, participation in sports, wearing socks and shoes, and attending school or going to work." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1163/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/etha/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1163/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A507FE040A3610000000003DC0160.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1163_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1163_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/scn8a-ee/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/myo-dystonia/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1163_"><span class="title" itemprop="name"><i>SCN9A</i>-Related Inherited Erythromelalgia</span></h1><p class="contrib-group"><span itemprop="author">Fuki M Hisama</span>, MD, <span itemprop="author">Sulayman D Dib-Hajj</span>, PhD, and <span itemprop="author">Stephen G Waxman</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1163_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1163_ai__"><div class="contrib half_rhythm"><span itemprop="author">Fuki M Hisama</span>, MD<div class="affiliation small">Division of Genetics<br />Department of Medicine<br />University of Washington<br />Seattle, Washington<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.notgnihsaw.u@2hmf" class="oemail">ude.notgnihsaw.u@2hmf</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Sulayman D Dib-Hajj</span>, PhD<div class="affiliation small">Senior Research Scientist, Center for Neuroscience and Regeneration Research<br />Department of Neurology<br />Yale University School of Medicine<br />New Haven, Connecticut<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.elay@jjah-bid.namyalus" class="oemail">ude.elay@jjah-bid.namyalus</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Stephen G Waxman</span>, MD, PhD<div class="affiliation small">Professor and Chair, Center for Neuroscience and Regeneration Research<br />Department of Neurology<br />Yale University School of Medicine<br />New Haven, Connecticut<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.elay@namxaw.nehpets" class="oemail">ude.elay@namxaw.nehpets</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">May 6, 2006</span>; Last Update: <span itemprop="dateModified">August 15, 2013</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="etha.Summary" itemprop="description"><h2 id="_etha_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM) is characterized by recurrent attacks of bilateral and symmetric intense pain, redness, warmth, and swelling involving the feet and, less frequently, the hands. <i>SCN9A</i>-related IEM is not associated with an organic disease. Manifestations may vary within a family. Onset is usually in childhood or adolescence but has been recognized in infants and adults. At onset, episodes are triggered by warmth; other precipitating factors include: exercise, tight shoes, wearing socks, alcohol, spicy foods, and other vasodilating agents. In advanced disease, symptoms may occur many times a day or become constant. Some individuals have allodynia (pain evoked by a normally innocuous stimulus) and hyperalgesia (increased <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> to a painful stimulus). Episodes may be disabling, interfere with sleep, and severely limit normal activities such as walking, participation in sports, wearing socks and shoes, and attending school or going to work.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>SCN9A</i>-related IEM is made on clinical grounds. Pathogenic variants in <i>SCN9A</i> encoding the sodium channel protein Na<sub>v</sub>1.7 subunit are known to cause IEM; pathogenic variants in additional genes may also be associated with IEM.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Pain is often refractory to treatment; no treatment is consistently effective. Treatment is individualized and depends on other medical conditions, known medication allergies, and potential for drug-drug interactions. Drugs shown to be effective in relieving pain in some individuals include: aspirin, misoprostol, serotonin-norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors, gabapentin, sodium channel blockers, carbamazepine, tricyclic antidepressants, calcium antagonists, magnesium, sodium nitroprusside infusion, and cyclosporine. Other treatments include: sympathetic block, surgical sympathectomy, and epidural infusion of opiates. Cooling of the extremities typically reduces pain in a symptomatic person.</p><p><i>Prevention of primary manifestations:</i> Avoidance of triggers (warmth, prolonged standing) may reduce the number or severity of episodes.</p><p><i>Prevention of secondary complications:</i> Secondary complications from prolonged immersion in ice baths include: skin maceration, infection, and gangrene; cooling with a fan is generally safer than immersion in water.</p><p><i>Surveillance:</i> There are no published guidelines for surveillance; however, it is important to monitor for side effects of treatment.</p><p><i>Agents/circumstances to avoid:</i> Heat, standing, alcohol, and spicy foods may trigger symptoms.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>SCN9A</i>-related IEM is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%. Each child of an individual with an <i>SCN9A</i>-related IEM <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has a 50% chance of inheriting the variant.</p></div></div><div id="etha.Diagnosis"><h2 id="_etha_Diagnosis_">Diagnosis</h2><div id="etha.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>The diagnosis of <i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM) &#x02013; also known as primary erythromelalgia or erythermalgia &#x02013; is made on clinical grounds.</p><p><i>SCN9A</i>-related IEM is characterized by recurrent episodes of bilateral intense, burning pain; redness; warmth; and (occasionally) swelling affecting the distal extremities. The feet are more commonly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> than the hands, but, in severely affected individuals, symptoms may involve the legs, arms, face, or ears.</p><p>Note: If symptoms are intermittent, photographs of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> extremities during a flare can help with diagnosis (see <a class="figpopup" href="/books/NBK1163/figure/etha.F1/?report=objectonly" target="object" rid-figpopup="figethaF1" rid-ob="figobethaF1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figethaF1" co-legend-rid="figlgndethaF1"><a href="/books/NBK1163/figure/etha.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figethaF1" rid-ob="figobethaF1"><img class="small-thumb" src="/books/NBK1163/bin/etha-Image001.gif" src-large="/books/NBK1163/bin/etha-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndethaF1"><h4 id="etha.F1"><a href="/books/NBK1163/figure/etha.F1/?report=objectonly" target="object" rid-ob="figobethaF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Red and swollen feet of an individual with <i>SCN9A</i>-related IEM </p></div></div><p><i>SCN9A</i>-related IEM is not associated with an organic disease.</p><p>Note: In the initial evaluation of painful, erythematous extremities, other treatable conditions resulting in secondary EM must be excluded (see <a href="#etha.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>The disorder is confirmed by detection of an <i>SCN9A</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a clinical laboratory.</p></div><div id="etha.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p><b>Gene.</b> Pathogenic variants in <i>SCN9A</i> encoding the sodium channel protein Na<sub>v</sub>1.7 subunit are known to cause IEM [<a class="bk_pop" href="#etha.REF.yang.2004.171">Yang et al 2004</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.michiels.2005.1587">Michiels et al 2005</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>, <a class="bk_pop" href="#etha.REF.lee.2007.210">Lee et al 2007</a>, <a class="bk_pop" href="#etha.REF.takahashi.2007.157">Takahashi et al 2007</a>].</p><p><b>Evidence for <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity</b></p><ul><li class="half_rhythm"><div>Linkage to <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2q was excluded in a three-generation family [<a class="bk_pop" href="#etha.REF.burns.2005.174">Burns et al 2005</a>], suggesting the possible existence of additional genes in which mutation is causative.</div></li><li class="half_rhythm"><div>Exclusion of pathogenic variants in <i>SCN9A</i>, <i>SCN10A</i>, and <i>SCN11A</i> in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases also supports genetic heterogeneity [<a class="bk_pop" href="#etha.REF.drenth.2008.320">Drenth et al 2008</a>].</div></li></ul><div id="etha.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>SCN9A</i>-Related Inherited Erythromelalgia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1163/table/etha.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__etha.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="col" colspan="1" headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="3" scope="col" colspan="1" headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="3" scope="col" colspan="1" headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_3" style="text-align:left;vertical-align:middle;">Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency&#x000a0;<sup>3,&#x000a0;4</sup></th></tr><tr><th headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Family History&#x000a0;<sup>5</sup></th></tr><tr><th headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_etha.T.molecular_genetic_testing_used_in_1_1_2_1" id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_3_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Positive</th><th headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_etha.T.molecular_genetic_testing_used_in_1_1_2_1" id="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</th></tr></thead><tbody><tr><td headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SCN9A</i></td><td headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>6</sup></td><td headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants</td><td headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_etha.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_etha.T.molecular_genetic_testing_used_in_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%-100%</td><td headers="hd_h_etha.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_etha.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_etha.T.molecular_genetic_testing_used_in_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~30%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="etha.TF.1.1"><p class="no_margin">See <a href="/books/NBK1163/#etha.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="etha.TF.1.2"><p class="no_margin">See <a href="#etha.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="etha.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="etha.TF.1.4"><p class="no_margin">Because so few individuals have been tested to date, detection rates need to be considered preliminary.</p></div></dd><dt>5. </dt><dd><div id="etha.TF.1.5"><p class="no_margin">Variant detection frequency differs depending on whether the family history is positive (i.e., other family members are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>) or negative (no other family members are affected) [<a class="bk_pop" href="#etha.REF.yang.2004.171">Yang et al 2004</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.michiels.2005.1587">Michiels et al 2005</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>, <a class="bk_pop" href="#etha.REF.lee.2007.210">Lee et al 2007</a>, <a class="bk_pop" href="#etha.REF.takahashi.2007.157">Takahashi et al 2007</a>, <a class="bk_pop" href="#etha.REF.drenth.2008.320">Drenth et al 2008</a>].</p></div></dd><dt>6. </dt><dd><div id="etha.TF.1.6"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd></dl></div></div></div></div><div id="etha.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>,</b> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>SCN9A</i> is performed.</p><p><i>SCN9A</i> may also be represented on <b>multigene panels</b> used to evaluate individuals with seizure disorders. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><p><b>Prenatal diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> (PGD)</b> for at-risk pregnancies require prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p></div></div><div id="etha.Clinical_Characteristics"><h2 id="_etha_Clinical_Characteristics_">Clinical Characteristics</h2><div id="etha.Clinical_Description"><h3>Clinical Description</h3><p><i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM) is characterized by recurrent attacks of intense pain, redness, warmth, and swelling involving the feet and, less frequently, the hands [<a class="bk_pop" href="#etha.REF.dibhajj.2007.555">Dib-Hajj et al 2007</a>, <a class="bk_pop" href="#etha.REF.drenth.2007.3603">Drenth &#x00026; Waxman 2007</a>]. Warmth is an essential part of the syndrome. During the attacks, the extremities appear red or purple and may be swollen. Commonly, the attacks occur in the evening or at night and so may not be observed by a physician. The individual may seek medical advice for painful extremities but neglect to mention the characteristic warmth or redness (especially if limited to the soles of the feet). The symptoms are usually bilateral and symmetric. Within a family, the manifestations of the disorder may vary considerably.</p><p>Onset of <i>SCN9A</i>-related IEM is usually in childhood or adolescence; however, it has been recognized in infants in families who are familiar with the disorder. Although rare, onset of <i>SCN9A</i>-related IEM has been reported in individuals or families after age 20 years [<a class="bk_pop" href="#etha.REF.choi.2010.1823">Choi et al 2010</a>].</p><p>Initially, the symptoms involve the soles of the feet and the hands; with age, the lower legs and the arms may become involved. In individuals with advanced disease, symptoms may occur many times a day and last hours, especially at night, or become constant and unremitting.</p><p>At the onset, the episodes are triggered by exposure to warmth. A pathognomonic feature is triggering of episodes by warm or hot ambient temperature and relief with cooling of the extremities.</p><p>Less consistent precipitating factors include: exercise, tight shoes, wearing socks, alcohol, spicy foods, and other vasodilating agents.</p><p>Some individuals have allodynia (pain evoked by a normally innocuous stimulus) and hyperalgesia (increased <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> to a painful stimulus).</p><p>The episodes may be disabling, interfere with sleep, and severely limit normal activities such as walking, participation in sports, wearing socks and shoes, and attending school or going to work. Individuals tend to limit their activities in warm weather and to stay in air-conditioned environments. Some individuals move from hot, humid climates to cooler climates.</p><p>Affected individuals prefer to wear open-toed shoes and to sleep with their feet uncovered. Swimming can be helpful because it keeps the limbs cool during exercise.</p><p><b>Neurologic examination</b> is typically normal, although reduced ankle reflexes and decreased distal sensation can be seen.</p><p><b>Electrophysiologic studies.</b> Nerve conduction velocity studies and electromyography were reported to be abnormal in 14 of 24 individuals with "<a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a>" erythermalgia [<a class="bk_pop" href="#etha.REF.davis.2003.1337">Davis et al 2003</a>]. It is unknown if the prevalence of electrophysiologic abnormalities is similar in individuals with <i>SCN9A</i>-related IEM.</p><p><b>Histopathologic examination</b> of skin biopsy shows nonspecific thickening of blood vessel basement membrane, perivascular edema and mononuclear infiltrate, and reduced density of the autonomic nerve plexuses.</p><p><b>Pathophysiology.</b> Underlying mechanisms that have been proposed:</p><ul><li class="half_rhythm"><div>Alterations in microvascular blood flow or capillary density [<a class="bk_pop" href="#etha.REF.m_rk.2000a.643">M&#x000f8;rk et al 2000a</a>, <a class="bk_pop" href="#etha.REF.m_rk.2002.949">M&#x000f8;rk et al 2002</a>, <a class="bk_pop" href="#etha.REF.davis.2003.1337">Davis et al 2003</a>]</div></li><li class="half_rhythm"><div>Interplay between neural and vasoactive agents [<a class="bk_pop" href="#etha.REF.littleford.1999.507">Littleford et al 1999</a>]</div></li><li class="half_rhythm"><div>Small-fiber neuropathy [<a class="bk_pop" href="#etha.REF.davis.2003.1337">Davis et al 2003</a>, <a class="bk_pop" href="#etha.REF._rstavik.2003.567">&#x000d8;rstavik et al 2003</a>, <a class="bk_pop" href="#etha.REF._rstavik.2004.531">&#x000d8;rstavik et al 2004</a>]</div></li></ul><p>Although vasculopathy and neuropathy may coexist in individuals with primary or secondary EM, it is not possible to distinguish cause from secondary effects.</p></div><div id="etha.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Disease severity varies within families; whether the cause of the variation is genetic or environmental is unknown.</p><p>Age of onset of symptoms has been correlated with the degree of the shift in activation of the voltage-gated sodium channel produced by pathogenic variants in <i>SCN9A</i>, with older onset associated with smaller shifts in channel activation [<a class="bk_pop" href="#etha.REF.cheng.2008.1">Cheng et al 2008</a>, <a class="bk_pop" href="#etha.REF.han.2009.1711">Han et al 2009</a>].</p><p>Paroxysmal extreme pain disorder may be more responsive to carbamazepine than <i>SCN9A</i>-related IEM, which has a less consistent response. A correlation may exist between individual pathogenic variants and response to drugs that block the sodium channel [<a class="bk_pop" href="#etha.REF.drenth.2007.3603">Drenth &#x00026; Waxman 2007</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2013.49">Dib-Hajj et al 2013</a>].</p></div><div id="etha.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in families with <i>SCN9A</i>-related IEM reported to date is 100%; however, molecular genetic data are available for fewer than 30 families.</p></div><div id="etha.Anticipation"><h3>Anticipation</h3><p>Anticipation has not been reported.</p></div><div id="etha.Nomenclature"><h3>Nomenclature</h3><p>The term "erythromelalgia" was coined by the American neurologist S Weir Mitchell, MD, and is derived from the Greek words: erythro (red), melos (extremity), and algos (pain) [<a class="bk_pop" href="#etha.REF.mitchell.1878.2">Mitchell 1878</a>].</p><p>Some authors have proposed the term "erythermalgia" for the <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> genetic form of EM, and "erythromelalgia" for disease associated with an underlying medical condition or drug [<a class="bk_pop" href="#etha.REF.drenth.1994.393">Drenth &#x00026; Michiels 1994</a>].</p><p>Other authors prefer "erythromelalgia" for both <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> (primary) EM and acquired forms of the disease (secondary EM).</p></div><div id="etha.Prevalence"><h3>Prevalence</h3><p>No accurate data on the worldwide prevalence of <i>SCN9A</i>-related IEM are available.</p><p>One study estimated the prevalence of all forms of EM to be 2:100,000 in Norway [<a class="bk_pop" href="#etha.REF.kvernebo.1998.1">Kvernebo 1998</a>].</p><p>Thus far, families with a clinical diagnosis of erythromelalgia (some with an <i>SCN9A</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>) have been identified in Canada, China, Japan, Taiwan, France, Belgium, the Netherlands, the United Kingdom, and the United States [<a class="bk_pop" href="#etha.REF.sano.2003.816">Sano et al 2003</a>, <a class="bk_pop" href="#etha.REF.yang.2004.171">Yang et al 2004</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.michiels.2005.1587">Michiels et al 2005</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.lee.2007.210">Lee et al 2007</a>, <a class="bk_pop" href="#etha.REF.ahn.2010.944">Ahn et al 2010</a>].</p><p>It is likely that erythromelalgia is underdiagnosed or often misdiagnosed.</p></div></div><div id="etha.Genetically_Related_Allelic_Disorde"><h2 id="_etha_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><b>Extreme pain disorder.</b> Pathogenic variants in <i>SCN9A</i> have been reported in paroxysmal extreme pain disorder, previously termed <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> rectal pain (OMIM <a href="http://omim.org/entry/167400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">167400</a>) [<a class="bk_pop" href="#etha.REF.fertleman.2004">Fertleman et al 2004</a>, <a class="bk_pop" href="#etha.REF.fertleman.2006.1294">Fertleman &#x00026; Ferrie 2006</a>, <a class="bk_pop" href="#etha.REF.fertleman.2006.767">Fertleman et al 2006</a>, <a class="bk_pop" href="#etha.REF.fertleman.2007.586">Fertleman et al 2007</a>]. This <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorder is characterized by episodes of rectal, ocular, or submandibular pain accompanied by erythema.</p><p><b>Insensitivity to pain.</b> Pathogenic variants in <i>SCN9A</i> resulting in loss of function of sodium channel Na<sub>v</sub>1.7 subunit alpha cause channelopathy-associated <a href="/books/n/gene/cip-overview/">insensitivity to pain</a> [<a class="bk_pop" href="#etha.REF.cox.2006.894">Cox et al 2006</a>]. Three <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> pathogenic variants in <i>SCN9A</i> were identified in six <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from three <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> families. All affected children (age range: 4-14 years) had insensitivity to pain and were otherwise normal and healthy. Loss-of-function variants have been identified in patients from various ethnic backgrounds [<a class="bk_pop" href="#etha.REF.ahmad.2007.2114">Ahmad et al 2007</a>, <a class="bk_pop" href="#etha.REF.goldberg.2007.311">Goldberg et al 2007</a>].</p><p><b>Small fiber neuropathy.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>SCN9A</i> have been reported in eight of 28 adult (age &#x02265;18 years) individuals with small fiber neuropathy in whom known causes for small fiber neuropathy (e.g., diabetes mellitus, impaired glucose tolerance, hyperlipidemia) were excluded, and who met strict diagnostic criteria for <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> small fiber neuropathy [<a class="bk_pop" href="#etha.REF.faber.2012.26">Faber et al 2012</a>].</p><p><b>Febrile seizures and epilepsy.</b> Pathogenic variants in <i>SCN9A</i> have been reported in a large Utah family with generalized epilepsy febrile seizures plus (GEFS+) as well as in unrelated individuals with simple febrile seizures [<a class="bk_pop" href="#etha.REF.singh.2009.e1000649">Singh et al 2009</a>]. Clinical features include onset of childhood febrile seizures, persistence of afebrile seizures beyond childhood, and a broad range of seizure manifestations, including intractable epilepsy.</p></div><div id="etha.Differential_Diagnosis"><h2 id="_etha_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis of <i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM) includes <a href="#etha.Secondary_EM">secondary EM</a> resulting from an underlying organic disease, medication, or toxin; <a href="#etha.Neuropathies">neuropathies</a>; <a href="#etha.Other_Conditions">other conditions</a> with some overlapping features; and <a href="#etha.IEM_Not_Related_to_Mutation_of_SCN9">inherited erythromelalgia in which no <i>SCN9A</i> pathogenic variant</a> is identified.</p><div id="etha.Secondary_EM"><h3>Secondary EM</h3><p>Secondary erythromelalgia occurs in a variety of disorders and begins at any age. Medications and toxins are potentially reversible causes of secondary erythromelalgia:</p><ul><li class="half_rhythm"><div><b>Essential thrombocythemia,</b> a myeloproliferative disorder, is the most significant cause of secondary erythromelalgia, occurring in up to 25% of individuals with this condition [<a class="bk_pop" href="#etha.REF.drenth.1994.393">Drenth &#x00026; Michiels 1994</a>, <a class="bk_pop" href="#etha.REF.mccarthy.2002.1245">McCarthy et al 2002</a>]. Erythromelalgia is frequently the presenting complaint and may precede a diagnosis of myeloproliferative disease by several years. A significant clinical characteristic of erythromelalgia secondary to thrombocythemia is marked pain relief lasting up to several days following ingestion of a single dose of aspirin. Neither <i>SCN9A</i>-related IEM nor other forms of secondary EM demonstrate the same dramatic response to aspirin treatment.</div></li><li class="half_rhythm"><div><b>Polycythemia vera</b> or <b>thrombotic thrombocytopenic purpura</b></div></li><li class="half_rhythm"><div><b>Rheumatologic disorders</b> such as gout and <b>autoimmune disorders</b> including systemic lupus erythematosus (SLE), rheumatoid arthritis, or vasculitis</div></li><li class="half_rhythm"><div><b>Paraneoplastic syndrome,</b> a rare cause of secondary erythromelalgia [<a class="bk_pop" href="#etha.REF.m_rk.1999.394">M&#x000f8;rk et al 1999</a>]</div></li><li class="half_rhythm"><div><b>Medications</b> such as verapamil, nifedipine, bromocriptine, and ticlopidine [<a class="bk_pop" href="#etha.REF.yosipovitch.1999.473">Yosipovitch et al 1999</a>]</div></li><li class="half_rhythm"><div><b>Environmental toxins</b></div><ul><li class="half_rhythm"><div>Inorganic mercury poisoning, which produces acrodynia (erythema and edema of the hands and feet)</div></li><li class="half_rhythm"><div>Mushroom poisoning [<a class="bk_pop" href="#etha.REF.diaz.2005.427">Diaz 2005</a>]</div></li></ul></li></ul></div><div id="etha.Neuropathies"><h3>Neuropathies</h3><p>Painful neuropathies associated with diabetes mellitus, alcoholism, HIV infection, <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> small fiber neuropathy, and Lyme disease may cause burning pain similar to erythromelalgia but are much less likely to be associated with redness, warmth, heat intolerance, and relief with cooling [<a class="bk_pop" href="#etha.REF.m_rk.2000b.498">M&#x000f8;rk et al 2000b</a>].</p></div><div id="etha.Other_Conditions"><h3>Other Conditions</h3><p><b>Reflex sympathetic dystrophy (RSD),</b> a complex regional pain syndrome, may be indistinguishable from <i>SCN9A</i>-related IEM in its early stages; however, RSD is much more likely to be unilateral. RSD usually follows an injury in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> limb, such as a wrist fracture, typically evolves to include signs such as reduced circulation, and may also be associated with changes in the nails, joints, or bone density [<a class="bk_pop" href="#etha.REF.schott.2001.291">Schott 2001</a>].</p><p><b>Peripheral vascular disease</b> may be associated with pain of the distal extremities triggered by exercise (claudication) and, with chronic disease, cause change in skin color. Peripheral vascular disease is associated with smoking and cardiovascular or cerebrovascular disease.</p><p><b>Raynaud's phenomenon,</b> in contrast to <i>SCN9A</i>-related IEM, is typically exacerbated by exposure to cold, with vasospasm, pain, and skin color changes.</p><p><a href="/books/n/gene/fabry/"><b>Fabry disease</b></a> causes burning pain of the distal extremities in childhood but is differentiated by an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> pattern of inheritance and other clinical features including angiokeratomas, characteristic corneal and lenticular opacities, and increased occurrence of renal and cerebrovascular disease.</p></div><div id="etha.IEM_Not_Related_to_Mutation_of_SCN9"><h3>IEM Not Related to Mutation of <i>SCN9A</i></h3><p>A three-generation family with EM, in which pathogenic variants in <i>SCN9A</i> were excluded by variant screening and linkage to the <i>SCN9A</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> was excluded by linkage analysis and haplotype analysis, has been reported [<a class="bk_pop" href="#etha.REF.burns.2005.174">Burns et al 2005</a>]. A distinctive clinical feature was an age of onset ranging from 21 years to 76 years. The molecular basis of this condition is unknown.</p><p>Additional families with IEM have been tested for pathogenic variants in <i>SCN9A</i>, <i>SCN10A</i>, and <i>SCN11A</i> with normal results, lending additional support for genetic heterogeneity in this condition [<a class="bk_pop" href="#etha.REF.drenth.2008.320">Drenth et al 2008</a>].</p></div></div><div id="etha.Management"><h2 id="_etha_Management_">Management</h2><div id="etha.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM), the following are recommended:</p><ul><li class="half_rhythm"><div>Assessment of the pain management strategies used (see <a href="#etha.Treatment_of_Manifestations">Treatment of Manifestations</a>)</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="etha.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>The pain of <i>SCN9A</i>-related IEM or secondary erythromelalgia is often refractory to treatment.</p><p>Reports on treatments in a series involve heterogeneous populations. In a report of 169 individuals with erythromelalgia of mixed etiologies, 84 medications or treatments were used [<a class="bk_pop" href="#etha.REF.davis.2000.330">Davis et al 2000</a>]. Response is highly variable, and no treatment is consistently effective. No controlled treatment trial has compared the effectiveness of various classes of medications.</p><p><b>Cooling the extremities</b> reduces pain in a symptomatic person.</p><p><b>Medications.</b> The effectiveness of medications and the order in which they should be tried is highly controversial, according to a consensus of expert opinion. Treatment should be determined by the individual's treating physician, based on factors including other medical conditions, known medication allergies, and potential for drug-drug interactions.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Aspirin</b> should be tried because of the known, dramatic response of thrombocythemia-associated EM to low-dose aspirin. A positive response warrants evaluation for and monitoring for myeloproliferative disease because the symptoms of thrombocythemia-associated EM may precede a diagnosis by several years. If pain is not relieved, aspirin should be discontinued.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Misoprostol,</b> an oral prostaglandin E1 analog, was tested in a double-blind, placebo-controlled, one-way crossover clinical trial in 21 adults with erythromelalgia and 11 healthy controls. Improvements in pain and cooling scores were significant (p&#x0003c;0.01) [<a class="bk_pop" href="#etha.REF.m_rk.2004.587">M&#x000f8;rk et al 2004</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Seratonin-norepinephrine reuptake inhibitors (SNRIs) / selective serotonin reuptake inhibitors (SSRIs).</b> Venlafaxine, an SNRI, has induced remissions in approximately a dozen individuals even after other classes of medications have been unsuccessful [<a class="bk_pop" href="#etha.REF.dicaudo.2004.621">DiCaudo &#x00026; Kelley 2004</a>]. SSRIs (fluoxetine, sertraline) have been reported to be helpful in some additional <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Gabapentin</b> has been one of the more effective medical treatments in both primary and secondary EM. Of 16 individuals taking gabapentin in a survey of Erythromelalgia Association members, all 16 reported benefit, although the degree was not quantified. Experts have reported typically mild to moderate pain relief. Remissions (i.e., remaining pain-free for 4-6 months) on gabapentin have been reported in an adult and a child [<a class="bk_pop" href="#etha.REF.cohen.2000.841">Cohen 2000</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Sodium channel blockers</b> including lidocaine infusion, lidocaine patch, or oral mexilitine have been used successfully in inherited erythromelalgia and secondary erythromelalgia [<a class="bk_pop" href="#etha.REF.kuhnert.1999.1447">Kuhnert et al 1999</a>, <a class="bk_pop" href="#etha.REF.davis.2005.1320">Davis &#x00026; Sandroni 2005</a>, <a class="bk_pop" href="#etha.REF.nathan.2005.e504">Nathan et al 2005</a>, <a class="bk_pop" href="#etha.REF.choi.2009.383">Choi et al 2009</a>]. Because of the absence of systemic side effects, partial relief in 55% of the individuals studied, and greater than 80% pain relief in 12% of individuals, <a class="bk_pop" href="#etha.REF.davis.2005.1320">Davis &#x00026; Sandroni [2005]</a> have suggested a lidocaine patch as first-line treatment. It is not known whether sodium channel blockers are more effective in individuals with <i>SCN9A</i>-related IEM than in individuals with other forms of EM.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Carbamazepine.</b> In a survey of 41 members of the Erythromelalgia Association, one of four persons using carbamazepine reported improvement [<a class="bk_pop" href="#etha.REF.cohen.2000.841">Cohen 2000</a>]. A family with a known <i>SCN9A</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Val400Met) reported significant improvement of symptoms while using carbamazepine [<a class="bk_pop" href="#etha.REF.fischer.2009.733">Fischer et al 2009</a>].</div><div class="half_rhythm">The combination of carbamazepine and gabapentin has been reported to produce relief in one individual with <i>SCN9A</i>-related IEM [<a class="bk_pop" href="#etha.REF.natkunarajah.2009.e640">Natkunarajah et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Oxcarbazepine</b> use in treating EM has not been reported.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Tricyclic antidepressants</b> used alone or in combination with other classes of medications have reduced pain. Their use has diminished with the introduction of newer agents with a more favorable side-effect profile, but they should be considered in refractory individuals. Topical application of 1.0% amitriptyline hydrochloride and 0.5% ketamine hydrochloride in pluronic lecithin organogel has been reported effective in four of five patients with refractory EM [<a class="bk_pop" href="#etha.REF.sandroni.2006.283">Sandroni &#x00026; Davis 2006</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Calcium antagonists.</b> Diltiazem is very effective in some individuals, inducing at least one remission. Paradoxically, diltiazem and other calcium channel antagonists have been reported to trigger secondary EM.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Magnesium.</b> In 13 persons, high doses of oral magnesium induced remission in one person, improved symptoms in seven, did not change them in four, and exacerbated symptoms in one. Diarrhea was a limiting side effect [<a class="bk_pop" href="#etha.REF.cohen.2002.255">Cohen 2002</a>]. Remission (freedom from pain) was also reported in an Italian child [<a class="bk_pop" href="#etha.REF.dellera.2004.125">Dell'era et al 2004</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Sodium nitroprusside infusion</b> has been successful in the acute hospital setting in individuals with severe attacks [<a class="bk_pop" href="#etha.REF.chan.2002.229">Chan et al 2002</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Cyclosporine</b> was successful in one person with erythromelalgia. The postulated mechanism was inhibition of nitric oxide synthase in vascular smooth muscle and endothelial cells [<a class="bk_pop" href="#etha.REF.sano.2003.816">Sano et al 2003</a>]. Conversely, cyclosporine caused EM in another individual treated for psoriasis vulgaris [<a class="bk_pop" href="#etha.REF.thami.2003.910">Thami &#x00026; Bhalla 2003</a>].</div></li></ul><p><b>Sympathetic block, surgical sympathectomy, and epidural infusion</b></p><ul><li class="half_rhythm"><div>Sympathetic block has had mixed results in individuals with severe symptoms. Some have improved, some have not improved, and others have worsened [<a class="bk_pop" href="#etha.REF.cohen.2000.841">Cohen 2000</a>]. Sympathetic block should be tried &#x02013; and the response to repeated blocks considered &#x02013; prior to surgical sympathectomy.</div></li><li class="half_rhythm"><div>In at least two individuals, sympathectomy reduced redness but not pain.</div></li><li class="half_rhythm"><div>Epidural infusions of opiates have been used in combination with bupivicaine and other oral and topical medications with good results in a few individuals.</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div>Reports of a single or a few individuals have noted remission or significant improvement with cyproheptadine, propranolol, or thalamic stimulation [<a class="bk_pop" href="#etha.REF.delye.2005.e404">Delye et al 2005</a>].</div></li><li class="half_rhythm"><div>Additional combinations of medical, surgical, and alternative treatments tried with varying success in individuals with either primary EM or secondary EM are summarized by <a class="bk_pop" href="#etha.REF.davis.2000.330">Davis et al [2000]</a> (see Table 2) and <a class="bk_pop" href="#etha.REF.cohen.2000.841">Cohen [2000]</a> (see Table 3).</div></li></ul></div><div id="etha.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Avoidance of triggers (warmth, prolonged standing) may reduce the number or severity of episodes.</p></div><div id="etha.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Secondary complications from prolonged immersion in ice baths include: skin maceration, infection, and gangrene. Amputation has occasionally been necessary to treat these complications.</p><p>Cooling with a fan is generally safer than immersion in water.</p></div><div id="etha.Surveillance"><h3>Surveillance</h3><p>There are no published guidelines for surveillance. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are treated in dermatology clinics, neurology clinics, or pain clinics, or by anesthesiologists specializing in the management of chronic pain. It is important to monitor for side effects of treatment.</p></div><div id="etha.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Symptoms are triggered by warmth and standing and, in some individuals, by alcohol and spicy foods including chili peppers or garlic.</p><p>In some individuals, exercise can trigger symptoms. However, for many individuals, the benefits of mild exercise outweigh the disadvantages. Swimming is a preferred exercise because the extremities remain cool.</p></div><div id="etha.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#etha.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="etha.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Potential teratogenic effects of medications given for treatment of erythromelalgia should be discussed with <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> women of childbearing age. The ideal time to discuss this is prior to conception.</p></div><div id="etha.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Small molecule inhibitors of the <i>SCN9A</i> encoded sodium channel Na<sub>v</sub>1.7 have been developed. In one exploratory, randomized, double-blind crossover trial of four subjects with EM in whom the presence of <i>SCN9A</i> pathogenic variants had been confirmed, the compound was reported to be more effective than placebo in reducing the amount of pain for two hours following a pain induction stimulus [<a class="bk_pop" href="#etha.REF.goldberg.2012.80">Goldberg et al 2012</a>]. Given the small number of treated individuals and short duration of the study, strong conclusions cannot be drawn from these results.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="etha.Genetic_Counseling"><h2 id="_etha_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="etha.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="etha.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Many individuals diagnosed with <i>SCN9A</i>-related IEM have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <i>SCN9A</i>-related IEM may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by <i>de novo</i> pathogenic variants is unknown because the evaluation of family members for milder symptoms has been incomplete and molecular genetic data are insufficient.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include: a detailed clinical and family history and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of both parents if the pathogenic variant has been identified in the proband. In a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (individual with no known family history of <i>SCN9A</i>-related IEM), the data on heritability are incomplete.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, it is likely that the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The risk to the sibs of a proband appears to be low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs with an unaffected mosaic father have been reported [<a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with an IEM-causing variant in <i>SCN9A</i> has a 50% chance of inheriting the variant.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="etha.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has clinical evidence of the disorder or the pathogenic variant, it is likely that the proband has a <i>de novo</i> pathogenic variant. However, possible non-medical explanations, including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption, could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="etha.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SCN9A</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="etha.Resources"><h2 id="_etha_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Erythromelalgia Association</b></div><div>24 Pickering Lane</div><div>Wethersfield CT 06109</div><div><b>Phone:</b> 860-529-5261</div><div><a href="http://www.erythromelalgia.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.erythromelalgia.org</a></div></li></ul></div><div id="etha.Molecular_Genetics"><h2 id="_etha_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="etha.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>SCN9A-Related Inherited Erythromelalgia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1163/table/etha.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__etha.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_etha.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_etha.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_etha.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_etha.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_etha.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_etha.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_etha.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6335" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SCN9A</i></a></td><td headers="hd_b_etha.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6335" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q24<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_etha.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q15858" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sodium channel protein type 9 subunit alpha</a></td><td headers="hd_b_etha.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SCN9A" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCN9A database</a></td><td headers="hd_b_etha.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SCN9A" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCN9A</a></td><td headers="hd_b_etha.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SCN9A[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SCN9A</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="etha.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="etha.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for SCN9A-Related Inherited Erythromelalgia (<a href="/omim/133020,603415" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1163/table/etha.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__etha.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/133020" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">133020</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ERYTHERMALGIA, PRIMARY</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603415" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603415</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT; SCN9A</td></tr></tbody></table></div></div><div id="etha.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>A number of reviews [<a class="bk_pop" href="#etha.REF.waxman.2005a.785">Waxman &#x00026; Dib-Hajj 2005a</a>, <a class="bk_pop" href="#etha.REF.waxman.2005b.555">Waxman &#x00026; Dib-Hajj 2005b</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2007.555">Dib-Hajj et al 2007</a>, <a class="bk_pop" href="#etha.REF.drenth.2007.3603">Drenth &#x00026; Waxman 2007</a>] describe the molecular genetic pathogenesis of <i>SCN9A</i>-related inherited erythromelalgia (<i>SCN9A</i>-related IEM), which is associated with mutation of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that encodes the sodium channel protein type 9 alpha subunit (also known as the voltage-gated sodium channel subunit alpha Na<sub>v</sub>1.7) [<a class="bk_pop" href="#etha.REF.drenth.2001.1277">Drenth et al 2001</a>, <a class="bk_pop" href="#etha.REF.yang.2004.171">Yang et al 2004</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.michiels.2005.1587">Michiels et al 2005</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>, <a class="bk_pop" href="#etha.REF.lee.2007.210">Lee et al 2007</a>, <a class="bk_pop" href="#etha.REF.takahashi.2007.157">Takahashi et al 2007</a>]. The Na<sub>v</sub>1.7 sodium channel is preferentially expressed within dorsal root ganglia and sympathetic ganglion neurons [<a class="bk_pop" href="#etha.REF.djouhri.2003.565">Djouhri et al 2003</a>]. These pathogenic variants alter the biophysical properties of the channel by shifting activation in a hyperpolarizing direction (thus lowering the threshold for channel opening) by slowing deactivation (thus keeping the channel open longer) and by increasing the response of the channel to small, slow depolarizations close to the resting potential [<a class="bk_pop" href="#etha.REF.cummins.2004.8232">Cummins et al 2004</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.choi.2006.1563">Choi et al 2006</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>, <a class="bk_pop" href="#etha.REF.lampert.2006.36029">Lampert et al 2006</a>, <a class="bk_pop" href="#etha.REF.sheets.2007.1019">Sheets et al 2007</a>, <a class="bk_pop" href="#etha.REF.cheng.2008.1">Cheng et al 2008</a>]. The effects of these changes in channel properties have been studied within dorsal root ganglia neurons, in which they increase excitability and increase the frequency of firing [<a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>, <a class="bk_pop" href="#etha.REF.rush.2006.8245">Rush et al 2006</a>]. The Na<sub>v</sub>1.7 sodium channel is also expressed in neurons of the sympathetic ganglion. The expression of the IEM-causing variant p.Leu858His in superior cervical ganglion neurons (sympathetic neurons) causes these neurons to become less excitable [<a class="bk_pop" href="#etha.REF.rush.2006.8245">Rush et al 2006</a>], which may contribute to the loss of tonic cutaneous vasoconstriction associated with skin flushing in individuals with IEM. See <a class="figpopup" href="/books/NBK1163/table/etha.T.selected_scn9a_variants/?report=objectonly" target="object" rid-figpopup="figethaTselectedscn9avariants" rid-ob="figobethaTselectedscn9avariants">Table 2</a>.</p><p><b>Gene structure.</b>
<i>SCN9A</i> is composed of 26 exons spanning 167.3 Mb. Exon 5 (E5), which is 92 bp long, is present in embryonic/neonatal (E5N) and adult (E5A) <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> [<a class="bk_pop" href="#etha.REF.raymond.2004.46234">Raymond et al 2004</a>]. E5N is located upstream from E5A in <i>SCN9A</i>; the sequence encoded by these alternative exons differs by two amino acids only: Leu201 in E5N compared to Val201 in E5A (p.Leu201Val) and Asn206 in E5N compared to Asp206 in E5A (p.Asn206Asp). The control elements for this alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> and the functional effect of these variants have yet to be determined.</p><p>The utilization of an alternative 5' <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> for <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 12 lengthens <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 by 33 bp, leading to an extension of loop 1 (L1), which joins domains 1 and 2 by 11 amino acids for an Na<sub>v</sub>1.7 isoform of 1,988 amino acids [<a class="bk_pop" href="#etha.REF.raymond.2004.46234">Raymond et al 2004</a>]. The functional effect of the extension of L1 of Na<sub>v</sub>1.7 has yet to be determined.</p><p>The orthologs of <i>SCN9A</i> have been identified in rat and rabbit. The <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>-<a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> boundaries are highly conserved among rodent, rabbit, and human <i>SCN9A</i> in the regions that have been investigated. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1163/#etha.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK1163/table/etha.T.selected_scn9a_variants/?report=objectonly" target="object" rid-figpopup="figethaTselectedscn9avariants" rid-ob="figobethaTselectedscn9avariants">Table 2</a>. Twenty <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>SCN9A</i> have been identified and functionally validated in persons with <i>SCN9A</i>-related IEM and reported in public databases [reviewed in <a class="bk_pop" href="#etha.REF.dibhajj.2010.325">Dib-Hajj et al 2010</a>, <a class="bk_pop" href="#etha.REF.estacion.2013.99">Estacion et al 2013</a>]. The relative position of many pathogenic variants along the polypeptide is shown on the schematic of the channel in <a class="figpopup" href="/books/NBK1163/figure/etha.F2/?report=objectonly" target="object" rid-figpopup="figethaF2" rid-ob="figobethaF2">Figure 2</a>. An additional seven variants of unknown functional effects on the channel properties or link to disease are reported in professional (limited-access) databases.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figethaF2" co-legend-rid="figlgndethaF2"><a href="/books/NBK1163/figure/etha.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figethaF2" rid-ob="figobethaF2"><img class="small-thumb" src="/books/NBK1163/bin/etha-Image002.gif" src-large="/books/NBK1163/bin/etha-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndethaF2"><h4 id="etha.F2"><a href="/books/NBK1163/figure/etha.F2/?report=objectonly" target="object" rid-ob="figobethaF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">The exon/intron boundary in the genomic sequence of <i>SCN9A</i> </p></div></div><p>Some <i>SCN9A</i> mutated alleles:</p><ul><li class="half_rhythm"><div class="half_rhythm">p.Ile136Val in the S1 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> 1 [<a class="bk_pop" href="#etha.REF.lee.2007.210">Lee et al 2007</a>, <a class="bk_pop" href="#etha.REF.cheng.2008.1">Cheng et al 2008</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">p.Phe216Ser in the S4 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> I [<a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.choi.2006.1563">Choi et al 2006</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">p.Ser241Thr in the linker joining S4 and S5 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> I [<a class="bk_pop" href="#etha.REF.michiels.2005.1587">Michiels et al 2005</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">p.Asn395Lys in the S6 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> I [<a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">p.Leu823Arg in the S4 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> II [<a class="bk_pop" href="#etha.REF.takahashi.2007.157">Takahashi et al 2007</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">p.Ile848Thr, p.Leu858His, and p.Leu858Phe in the linker joining S4 and S5 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> II [<a class="bk_pop" href="#etha.REF.yang.2004.171">Yang et al 2004</a>, <a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.drenth.2008.320">Drenth et al 2008</a>]</div><div class="half_rhythm">Note: The contribution of the variant <a class="figpopup" href="/books/NBK1163/table/etha.T.selected_scn9a_variants/?report=objectonly" target="object" rid-figpopup="figethaTselectedscn9avariants" rid-ob="figobethaTselectedscn9avariants">p.Pro610Thr</a> to the disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is not clear at this time; p.Pro610Thr has been reported in the same individual along with the p.Leu858Phe <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in a multigenerational Canadian family [<a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>], suggesting that it is a <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> (<a href="/entrez/viewer.fcgi?val=NP_002968.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002968.1</a>). Protein change p.Leu858Phe was the only pathogenic variant reported in a Chinese individual; thus, this substitution alone is sufficient to alter the biophysical properties of mutated Na<sub>v</sub>1.7/p.Leu858Phe channels [<a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>], similar to the effect of the Na<sub>v</sub>1.7/p.Leu858His mutated channel [<a class="bk_pop" href="#etha.REF.cummins.2004.8232">Cummins et al 2004</a>]. Recently, analysis of the Canadian family has shown that p.Pro610Thr segregates independently of the p.Leu858Phe pathogenic variant and is present in one unaffected sib in this family and in 10/210 ethnically matched control chromosomes [<a class="bk_pop" href="#etha.REF.samuels.2008.21">Samuels et al 2008</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">p.Ala863Pro in the S5 of <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> II [<a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>]</div></li><li class="half_rhythm"><div class="half_rhythm">p.Phe1449Val in the linker joining domains III and IV [<a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>]</div></li></ul><div id="etha.T.selected_scn9a_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>SCN9A</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1163/table/etha.T.selected_scn9a_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__etha.T.selected_scn9a_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_etha.T.selected_scn9a_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_etha.T.selected_scn9a_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.601T&#x0003e;G</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu201Val</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_4" rowspan="14" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_002977.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002977<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?val=NP_002968.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002968<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.616A&#x0003e;G</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn206Asp</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.3448C&#x0003e;T</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1150Trp</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_1" rowspan="11" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.406A&#x0003e;G</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile136Val</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.647T&#x0003e;C</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe216Ser</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.721T&#x0003e;A</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser241Thr</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1185C&#x0003e;A</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn395Lys</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1828C&#x0003e;A</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro610Thr&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2468T&#x0003e;G</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu823Arg</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2543T&#x0003e;C</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile848Thr</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2573T&#x0003e;A</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu858His</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2572C&#x0003e;T</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu858Phe</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2587G&#x0003e;C</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala863Pro</td></tr><tr><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.4345T&#x0003e;G</td><td headers="hd_h_etha.T.selected_scn9a_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe1449Val</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="etha.TF.2.1"><p class="no_margin">The contribution of the variant p.Pro610Thr to the disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is not clear (see <b>Pathogenic variants</b>, Note).</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The normal product of <i>SCN9A</i> is the sodium channel protein type 9 alpha subunit (voltage-gated sodium channel Na<sub>v</sub>1.7). Na<sub>v</sub>1.7 comprises 1,977 amino acids organized into four domains, each with six transmembrane segments (S1-6), similar to members of the voltage-gated sodium and calcium ion channels [<a class="bk_pop" href="#etha.REF.catterall.2000.13">Catterall 2000</a>]. The channel produces a fast <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> sodium current that is sensitive to nanomolar concentrations of the neurotoxin tetrodotoxin (TTX-S). Na<sub>v</sub>1.7 is expressed predominantly in dorsal root ganglia neurons, particularly nociceptive neurons [<a class="bk_pop" href="#etha.REF.djouhri.2003.565">Djouhri et al 2003</a>] and sympathetic ganglion neurons [<a class="bk_pop" href="#etha.REF.rush.2006.8245">Rush et al 2006</a>]. Because of its slow closed-state inactivation, Na<sub>v</sub>1.7 produces depolarizing current in response to small depolarizing stimuli close to resting potential, thus amplifying small depolarizations such as generator potentials [<a class="bk_pop" href="#etha.REF.cummins.1998.9607">Cummins et al 1998</a>].</p><p><i>SCN9A</i> is expressed within dorsal root ganglion neurons and sympathetic ganglion neurons [<a class="bk_pop" href="#etha.REF.yang.2004.171">Yang et al 2004</a>, <a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>, <a class="bk_pop" href="#etha.REF.drenth.2005.1333">Drenth et al 2005</a>, <a class="bk_pop" href="#etha.REF.michiels.2005.1587">Michiels et al 2005</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.rush.2006.8245">Rush et al 2006</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Two pathogenic variants in <i>SCN9A</i> (p.Ile848Thr and p.Leu858His), identified in two Chinese families with <i>SCN9A</i>-related IEM, produce a hyperpolarizing shift in activation and slow deactivation, and enhance the channel's response to small depolarizing stimuli, changes that can confer hyperexcitability on cells in which the channel is expressed [<a class="bk_pop" href="#etha.REF.cummins.2004.8232">Cummins et al 2004</a>].</p><p>A third variant of <i>SCN9A</i> (p.Phe1449Val), from an American family with <i>SCN9A</i>-related IEM, produces a hyperpolarizing shift in activation and a depolarizing shift in steady-state inactivation and lowers thresholds of single action potentials and high-frequency firing in dorsal root ganglia neurons [<a class="bk_pop" href="#etha.REF.dibhajj.2005.1847">Dib-Hajj et al 2005</a>].</p><p>Several other pathogenic variants have been characterized by voltage-clamp recordings and show the common feature of hyperpolarizing shift in activation of the channel [<a class="bk_pop" href="#etha.REF.choi.2006.1563">Choi et al 2006</a>, <a class="bk_pop" href="#etha.REF.han.2006.553">Han et al 2006</a>, <a class="bk_pop" href="#etha.REF.harty.2006.12566">Harty et al 2006</a>, <a class="bk_pop" href="#etha.REF.lampert.2006.36029">Lampert et al 2006</a>, <a class="bk_pop" href="#etha.REF.sheets.2007.1019">Sheets et al 2007</a>, <a class="bk_pop" href="#etha.REF.cheng.2008.1">Cheng et al 2008</a>].</p></div></div><div id="etha.References"><h2 id="_etha_References_">References</h2><div id="etha.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="etha.REF.ahmad.2007.2114">Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE, Meijer IA, Meury L, Mills T, Moody A, Morinville A, Morten J, O'Donnell D, Raynoschek C, Salter H, Rouleau GA, Krupp JJ. A stop codon mutation in SCN9A causes lack of pain sensation. <span><span class="ref-journal">Hum Mol Genet. </span>2007;<span class="ref-vol">16</span>:2114–21.</span> [<a href="/pubmed/17597096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17597096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.ahn.2010.944">Ahn HS, Dib-Hajj SD, Cox JJ, Tyrrell L, Elmslie FV, Clarke AA, Drenth JP, Woods CG, Waxman SG. A new Na<sub>v</sub>1.7 sodium channel mutation I234T in a child with severe pain. <span><span class="ref-journal">Eur J Pain. </span>2010;<span class="ref-vol">14</span>:944–50.</span> [<a href="/pubmed/20385509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20385509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.burns.2005.174">Burns TM, Te Morsche RH, Jansen JB, Drenth JP. Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia. <span><span class="ref-journal">Br J Dermatol. </span>2005;<span class="ref-vol">153</span>:174–7.</span> [<a href="/pubmed/16029345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16029345</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.catterall.2000.13">Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. <span><span class="ref-journal">Neuron. </span>2000;<span class="ref-vol">26</span>:13–25.</span> [<a href="/pubmed/10798388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10798388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.chan.2002.229">Chan MK, Tucker AT, Madden S, Golding CE, Atherton DJ, Dillon MJ. Erythromelalgia: an endothelial disorder responsive to sodium nitroprusside. <span><span class="ref-journal">Arch Dis Child. </span>2002;<span class="ref-vol">87</span>:229–30.</span> [<a href="/pmc/articles/PMC1719230/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1719230</span></a>] [<a href="/pubmed/12193436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12193436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.cheng.2008.1">Cheng X, Dib-Hajj SD, Tyrrell L, Waxman SG. Mutation I136V alters electrophysiological properties of the Na<sub>v</sub>1.7 channel in a family with onset of erythromelalgia in the second decade. <span><span class="ref-journal">Mol Pain. </span>2008;<span class="ref-vol">4</span>:1.</span> [<a href="/pmc/articles/PMC2262064/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2262064</span></a>] [<a href="/pubmed/18171466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18171466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.choi.2006.1563">Choi JS, Dib-Hajj SD, Waxman SG. Inherited erythermalgia: limb pain from an S4 charge-neutral Na channelopathy. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:1563–7.</span> [<a href="/pubmed/16988069" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16988069</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.choi.2009.383">Choi JS, Zhang L, Dib-Hajj SD, Han C, Tyrrell L, Lin Z, Wang X, Yang Y, Waxman SG. Mexiletine-responsive erythromelalgia due to a new Na<sub>v</sub>1.7 mutation showing use-dependent current fall-off. <span><span class="ref-journal">Exp Neurol. </span>2009;<span class="ref-vol">216</span>:383–9.</span> [<a href="/pubmed/19162012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19162012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.choi.2010.1823">Choi JS, Cheng X, Foster E, Leffler A, Tyrrell L, Te Morsche RH, Eastman EM, Jansen HJ, Huehne K, Nau C, Dib-Hajj SD, Drenth JP, Waxman SG. Alternative splicing may contribute to time-dependent manifestation of inherited erythromelalgia. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:1823–35.</span> [<a href="/pubmed/20478850" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20478850</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.cohen.2000.841">Cohen JS. Erythromelalgia: new theories and new therapies. <span><span class="ref-journal">J Am Acad Dermatol. </span>2000;<span class="ref-vol">43</span>:841–7.</span> [<a href="/pubmed/11050591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11050591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.cohen.2002.255">Cohen JS. High-dose oral magnesium treatment of chronic, intractable erythromelalgia. <span><span class="ref-journal">Ann Pharmacother. </span>2002;<span class="ref-vol">36</span>:255–60.</span> [<a href="/pubmed/11847944" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11847944</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.cox.2006.894">Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG. An SCN9A channelopathy causes congenital inability to experience pain. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">444</span>:894–8.</span> [<a href="/pubmed/17167479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17167479</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.cummins.2004.8232">Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. <span><span class="ref-journal">J Neurosci. </span>2004;<span class="ref-vol">24</span>:8232–6.</span> [<a href="/pmc/articles/PMC6729696/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6729696</span></a>] [<a href="/pubmed/15385606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15385606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.cummins.1998.9607">Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. <span><span class="ref-journal">J Neurosci. </span>1998;<span class="ref-vol">18</span>:9607–19.</span> [<a href="/pmc/articles/PMC6793269/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6793269</span></a>] [<a href="/pubmed/9822722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9822722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.davis.2005.1320">Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. <span><span class="ref-journal">Arch Dermatol. </span>2005;<span class="ref-vol">141</span>:1320–1.</span> [<a href="/pubmed/16230578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16230578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.davis.2000.330">Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. <span><span class="ref-journal">Arch Dermatol. </span>2000;<span class="ref-vol">136</span>:330–6.</span> [<a href="/pubmed/10724194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10724194</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.davis.2003.1337">Davis MD, Sandroni P, Rooke TW, Low PA. Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia. <span><span class="ref-journal">Arch Dermatol. </span>2003;<span class="ref-vol">139</span>:1337–43.</span> [<a href="/pubmed/14568838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14568838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.dellera.2004.125">Dell'era L, Corona F, Lapidari A, Capanna S, Severgnini A, Costantini A, Bardare M, Carnelli V. Magnesium: a decisive therapy for erythromelalgia. <span><span class="ref-journal">Ital J Ped. </span>2004;<span class="ref-vol">30</span>:125–6.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.delye.2005.e404">Delye H, Lagae L, Vermylen J, Nuttin B. Thalamic stimulation as a treatment for primary erythromelalgia: technical case report. <span><span class="ref-journal">Neurosurgery. </span>2005;<span class="ref-vol">57</span>:E404.</span> [<a href="/pubmed/16234658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16234658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.diaz.2005.427">Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. <span><span class="ref-journal">Crit Care Med. </span>2005;<span class="ref-vol">33</span>:427–36.</span> [<a href="/pubmed/15699849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15699849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.dibhajj.2007.555">Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. From genes to pain: Nav1.7 and human pain disorders. <span><span class="ref-journal">Trends Neurosci. </span>2007;<span class="ref-vol">30</span>:555–63.</span> [<a href="/pubmed/17950472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17950472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.dibhajj.2005.1847">Dib-Hajj SD, Rush AM, Cummins TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:1847–54.</span> [<a href="/pubmed/15958509" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15958509</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.dibhajj.2010.325">Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. <span><span class="ref-journal">Annu Rev Neurosci. </span>2010;<span class="ref-vol">33</span>:325–47.</span> [<a href="/pubmed/20367448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20367448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.dibhajj.2013.49">Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na<sub>V</sub>1.7 sodium channel: from molecule to man. <span><span class="ref-journal">Nat Rev Neurosci. </span>2013;<span class="ref-vol">14</span>:49–62.</span> [<a href="/pubmed/23232607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23232607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.dicaudo.2004.621">DiCaudo DJ, Kelley LA. Alleviation of erythromelalgia with venlafaxine. <span><span class="ref-journal">Arch Dermatol. </span>2004;<span class="ref-vol">140</span>:621–3.</span> [<a href="/pubmed/15148116" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15148116</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.djouhri.2003.565">Djouhri L, Newton R, Levinson SR, Berry CM, Carruthers B, Lawson SN. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na+ channel alpha subunit protein. <span><span class="ref-journal">J Physiol (Lond). </span>2003;<span class="ref-vol">546</span>:565–76.</span> [<a href="/pmc/articles/PMC2342520/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2342520</span></a>] [<a href="/pubmed/12527742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12527742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.drenth.1994.393">Drenth JP, Michiels JJ. Erythromelalgia and erythermalgia: diagnostic differentiation. <span><span class="ref-journal">Int J Dermatol. </span>1994;<span class="ref-vol">33</span>:393–7.</span> [<a href="/pubmed/8056469" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8056469</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.drenth.2001.1277">Drenth JP, Finley WH, Breedveld GJ, Testers L, Michiels JJ, Guillet G, Taieb A, Kirby RL, Heutink P. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:1277–82.</span> [<a href="/pmc/articles/PMC1226108/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226108</span></a>] [<a href="/pubmed/11283792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11283792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.drenth.2005.1333">Drenth JP, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage-gated sodium channels. <span><span class="ref-journal">J Invest Dermatol. </span>2005;<span class="ref-vol">124</span>:1333–8.</span> [<a href="/pubmed/15955112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15955112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.drenth.2008.320">Drenth JP, Te Morsche RH, Mansour S, Mortimer PS. Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusions of a causal role of SCN10A and SCN11A. <span><span class="ref-journal">Arch Dermatol. </span>2008;<span class="ref-vol">144</span>:320–4.</span> [<a href="/pubmed/18347287" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18347287</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.drenth.2007.3603">Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. <span><span class="ref-journal">J Clin Invest. </span>2007;<span class="ref-vol">117</span>:3603–9.</span> [<a href="/pmc/articles/PMC2096434/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2096434</span></a>] [<a href="/pubmed/18060017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18060017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.estacion.2013.99">Estacion M, Yang Y, Dib-Hajj SD, Tyrrell L, Lin Z, Waxman SG. A new Na<sub>v</sub>1.7 mutation in an erythromelalgia patient. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2013;<span class="ref-vol">432</span>:99–104.</span> [<a href="/pubmed/23376079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23376079</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.faber.2012.26">Faber CG, Hoeijmakers JGJ, Ahn H-S, Cheng X, Han C, Choi J-S, Estacion M, Lauria G, Vanhoutte EK, Gerrits MM, Dib-Hajj S, Drenth JPH, Waxman SG, Merkles IJS. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. <span><span class="ref-journal">Ann Neurol. </span>2012;<span class="ref-vol">71</span>:26–39.</span> [<a href="/pubmed/21698661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21698661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.fertleman.2006.1294">Fertleman CR, Ferrie CD. What's in a name--familial rectal pain syndrome becomes paroxysmal extreme pain disorder. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2006;<span class="ref-vol">77</span>:1294–5.</span> [<a href="/pmc/articles/PMC2077381/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2077381</span></a>] [<a href="/pubmed/17043302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17043302</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.fertleman.2006.767">Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. <span><span class="ref-journal">Neuron. </span>2006;<span class="ref-vol">52</span>:767–74.</span> [<a href="/pubmed/17145499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17145499</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.fertleman.2007.586">Fertleman CR, Ferrie CD, Aicardi J, Bednarek NA, Eeg-Olofsson O, Elmslie FV, Griesemer DA, Goutieres F, Kirkpatrick M, Malmros IN, Pollitzer M, Rossiter M, Roulet-Perez E, Schubert R, Smith VV, Testard H, Wong V, Stephenson JB. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). <span><span class="ref-journal">Neurology. </span>2007;<span class="ref-vol">69</span>:586–95.</span> [<a href="/pubmed/17679678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17679678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.fertleman.2004">Fertleman CR, Rees M, Parker KA, Barlow E, Gardiner RM. Identification of the gene underlying an inherited disorder of pain sensation. Abstract 197. Toronto, Canada: American Society of Human Genetics Annual Meeting; 2004.</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.fischer.2009.733">Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M, Dib-Hajj SD, Waxman SG. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">65</span>:733–41.</span> [<a href="/pmc/articles/PMC4103031/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4103031</span></a>] [<a href="/pubmed/19557861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19557861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.goldberg.2007.311">Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. <span><span class="ref-journal">Clin Genet. </span>2007;<span class="ref-vol">71</span>:311–9.</span> [<a href="/pubmed/17470132" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17470132</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.goldberg.2012.80">Goldberg YP, Price N, Namderi R, Cohen CJ, Lamers MK, Winters C, Price J, Young CE, Verschoof H, Sherirington R, Pimstone SN, Hayden MR. Treatment of Nav1.7-mediated paiin in inherited erythromelalgia using a novel sodium channel blocker. <span><span class="ref-journal">Pain. </span>2012;<span class="ref-vol">153</span>:80–5.</span> [<a href="/pubmed/22035805" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22035805</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.han.2009.1711">Han C, Dib-Hajj SD, Lin Z, Li Y, Eastman EM, Tyrrell L, Cao X, Yang Y, Waxman SG. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:1711–22. <a href="/pubmed/19369487" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Early- and late-onset inherited erythromelalgia: genotype-phenotype correlation.</a></span> [<a href="/pubmed/19369487" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19369487</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.han.2006.553">Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Wang Y, Tyrrell L, Wang X, Yang Y, Waxman SG. Sporadic onset of erythermalgia: A gain-of-function mutation in Na(v)1.7. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">59</span>:553–8.</span> [<a href="/pubmed/16392115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16392115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.harty.2006.12566">Harty TP, Dib-Hajj SD, Tyrrell L, Blackman R, Hisama FM, Rose JB, Waxman SG. Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. <span><span class="ref-journal">J Neurosci. </span>2006;<span class="ref-vol">26</span>:12566–75.</span> [<a href="/pmc/articles/PMC6674913/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6674913</span></a>] [<a href="/pubmed/17135418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17135418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.kuhnert.1999.1447">Kuhnert SM, Phillips WJ, Davis MD. Lidocaine and mexiletine therapy for erythromelalgia. <span><span class="ref-journal">Arch Dermatol. </span>1999;<span class="ref-vol">135</span>:1447–9.</span> [<a href="/pubmed/10606048" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10606048</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.kvernebo.1998.1">Kvernebo K. Erythromelalgia: a condition caused by microvascular arteriovenous shunting. <span><span class="ref-journal">Vasa Suppl. </span>1998;<span class="ref-vol">51</span>:1–40.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.lampert.2006.36029">Lampert A, Dib-Hajj SD, Tyrrell L, Waxman SG. Size matters: erythromelalgia mutation S241T in Nav1.7 alters channel gating. <span><span class="ref-journal">J Biol Chem. </span>2006;<span class="ref-vol">281</span>:36029–35.</span> [<a href="/pubmed/17008310" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17008310</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.lee.2007.210">Lee MJ, Yu HS, Hsieh ST, Stephenson DA, Lu CJ, Yang CC. Characterization of a familial case with primary erythromelalgia from Taiwan. <span><span class="ref-journal">J Neurol. </span>2007;<span class="ref-vol">254</span>:210–14.</span> [<a href="/pubmed/17294067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17294067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.littleford.1999.507">Littleford RC, Khan F, Belch JJ. Impaired skin vasomotor reflexes in patients with erythromelalgia. <span><span class="ref-journal">Clin Sci (Lond). </span>1999;<span class="ref-vol">96</span>:507–12.</span> [<a href="/pubmed/10209083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10209083</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.mccarthy.2002.1245">McCarthy L, Eichelberger L, Skipworth E, Danielson C. Erythromelalgia due to essential thrombocythemia. <span><span class="ref-journal">Transfusion. </span>2002;<span class="ref-vol">42</span>:1245.</span> [<a href="/pubmed/12423504" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12423504</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.michiels.2005.1587">Michiels JJ, te Morsche RH, Jansen JB, Drenth JP. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:1587–90.</span> [<a href="/pubmed/16216943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16216943</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.mitchell.1878.2">Mitchell S. On a rare vaso-motor neurosis of the extremities, and on the maladies with which it may be confounded. <span><span class="ref-journal">Am J Med Sci. </span>1878;<span class="ref-vol">41</span>:2–36.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.m_rk.2000a.643">M&#x000f8;rk C, Asker CL, Salerud EG, Kvernebo K. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. <span><span class="ref-journal">J Invest Dermatol. </span>2000a;<span class="ref-vol">114</span>:643–6.</span> [<a href="/pubmed/10733667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10733667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.m_rk.1999.394">M&#x000f8;rk C, Kalgaard OM, Kvernebo K. Erythromelalgia as a paraneoplastic syndrome in a patient with abdominal cancer. <span><span class="ref-journal">Acta Derm Venereol. </span>1999;<span class="ref-vol">79</span>:394.</span> [<a href="/pubmed/10494725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10494725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.m_rk.2000b.498">M&#x000f8;rk C, Kalgaard OM, Myrvang B, Kvernebo K. Erythromelalgia in a patient with AIDS. <span><span class="ref-journal">J Eur Acad Dermatol Venereol. </span>2000b;<span class="ref-vol">14</span>:498–500.</span> [<a href="/pubmed/11444274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11444274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.m_rk.2002.949">M&#x000f8;rk C, Kvernebo K, Asker CL, Salerud EG. Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. <span><span class="ref-journal">J Invest Dermatol. </span>2002;<span class="ref-vol">119</span>:949–53.</span> [<a href="/pubmed/12406343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12406343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.m_rk.2004.587">M&#x000f8;rk C, Salerud EG, Asker CL, Kvernebo K. The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study. <span><span class="ref-journal">J Invest Dermatol. </span>2004;<span class="ref-vol">122</span>:587–93.</span> [<a href="/pubmed/15086539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15086539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.nathan.2005.e504">Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. <span><span class="ref-journal">Pediatrics. </span>2005;<span class="ref-vol">115</span>:e504–7.</span> [<a href="/pubmed/15741349" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15741349</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.natkunarajah.2009.e640">Natkunarajah J, Atherton D, Elmslie F, Mansour S, Mortimer P. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel. <span><span class="ref-journal">Clin Exp Dermatol. </span>2009;<span class="ref-vol">34</span>:e640–2.</span> [<a href="/pubmed/19549232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19549232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF._rstavik.2004.531">&#x000d8;rstavik K, M&#x000f8;rk C, Kvernebo K, J&#x000f8;rum E. Pain in primary erythromelalgia--a neuropathic component? <span><span class="ref-journal">Pain. </span>2004;<span class="ref-vol">110</span>:531–8.</span> [<a href="/pubmed/15288393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15288393</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF._rstavik.2003.567">&#x000d8;rstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, J&#x000f8;rum E, Handwerker H, Torebj&#x000f6;rk E. Pathological C-fibres in patients with a chronic painful condition. <span><span class="ref-journal">Brain. </span>2003;<span class="ref-vol">126</span>:567–78.</span> [<a href="/pubmed/12566278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12566278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.raymond.2004.46234">Raymond CK, Castle J, Garrett-Engele P, Armour CD, Kan Z, Tsinoremas N, Johnson JM. Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:46234–41.</span> [<a href="/pubmed/15302875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15302875</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.rush.2006.8245">Rush AM, Dib-Hajj SD, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2006;<span class="ref-vol">103</span>:8245–50.</span> [<a href="/pmc/articles/PMC1472458/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1472458</span></a>] [<a href="/pubmed/16702558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16702558</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.samuels.2008.21">Samuels ME, te Morsche RHM, Lynch ME, Drenth JPH. Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia. <span><span class="ref-journal">Mol Pain. </span>2008;<span class="ref-vol">4</span>:21.</span> [<a href="/pmc/articles/PMC2430949/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2430949</span></a>] [<a href="/pubmed/18518989" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18518989</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.sandroni.2006.283">Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? <span><span class="ref-journal">Arch Dermatol. </span>2006;<span class="ref-vol">142</span>:283–6.</span> [<a href="/pubmed/16549702" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16549702</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.sano.2003.816">Sano S, Itami S, Yoshikawa K. Treatment of primary erythromelalgia with cyclosporine. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>:816–7.</span> [<a href="/pubmed/12930941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12930941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.schott.2001.291">Schott GD. Reflex sympathetic dystrophy. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2001;<span class="ref-vol">71</span>:291–5.</span> [<a href="/pmc/articles/PMC1737569/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1737569</span></a>] [<a href="/pubmed/11511699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11511699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.sheets.2007.1019">Sheets PL, Jackson Ii JO, Waxman SG, Dib-Hajj S, Cummins TR. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. <span><span class="ref-journal">J Physiol (Lond). </span>2007;<span class="ref-vol">581</span>:1019–31.</span> [<a href="/pmc/articles/PMC2170829/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2170829</span></a>] [<a href="/pubmed/17430993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17430993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.singh.2009.e1000649">Singh NA, Pappas C, Dahle EJ, Claes LRF, Pruess TH., De Jonghe P, Thompson J, Dixon M, Gurnett C, Peiffer A, White HS., Filloux F, Leppert MF. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. <span><span class="ref-journal">PLoS Genet. </span>2009;<span class="ref-vol">5</span>:e1000649.</span> [<a href="/pmc/articles/PMC2730533/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2730533</span></a>] [<a href="/pubmed/19763161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19763161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.takahashi.2007.157">Takahashi K, Saitoh M, Hoshino H, Mimaki M, Yokoyama Y, Takamizawa M, Mizuguchi M, Lin ZM, Yang Y, Igarashi T. A case of primary erythermalgia, wintry hypothermia and encephalopathy. <span><span class="ref-journal">Neuropediatrics. </span>2007;<span class="ref-vol">38</span>:157–9.</span> [<a href="/pubmed/17985268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17985268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.thami.2003.910">Thami GP, Bhalla M. Erythromelalgia induced by possible calcium channel blockade by ciclosporin. <span><span class="ref-journal">BMJ. </span>2003;<span class="ref-vol">326</span>:910.</span> [<a href="/pmc/articles/PMC153834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC153834</span></a>] [<a href="/pubmed/12714471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12714471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.waxman.2005a.785">Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. <span><span class="ref-journal">Ann Neurol. </span>2005a;<span class="ref-vol">57</span>:785–8.</span> [<a href="/pubmed/15929046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15929046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.waxman.2005b.555">Waxman SG, Dib-Hajj SD. Erythermalgia: molecular basis for an inherited pain syndrome. <span><span class="ref-journal">Trends Mol Med. </span>2005b;<span class="ref-vol">11</span>:555–62.</span> [<a href="/pubmed/16278094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16278094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.yang.2004.171">Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, Fan J, Bu D, Liu B, Fan Z, Wu G, Jin J, Ding B, Zhu X, Shen Y. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:171–4.</span> [<a href="/pmc/articles/PMC1735695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735695</span></a>] [<a href="/pubmed/14985375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14985375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="etha.REF.yosipovitch.1999.473">Yosipovitch G, Rechavia E, Feinmesser M, David M. Adverse cutaneous reactions to ticlopidine in patients with coronary stents. <span><span class="ref-journal">J Am Acad Dermatol. </span>1999;<span class="ref-vol">41</span>:473–6.</span> [<a href="/pubmed/10459126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10459126</span></a>]</div></li></ul></div></div><div id="etha.Chapter_Notes"><h2 id="_etha_Chapter_Notes_">Chapter Notes</h2><div id="etha.Acknowledgments"><h3>Acknowledgments</h3><p>This work is supported in part by a gift from the Erythromelalgia Association.</p></div><div id="etha.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 August 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 September 2008 (cd) Revision: prenatal testing available</div></li><li class="half_rhythm"><div>26 August 2008 (cg) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 March 2007 (fmh) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> for <i>SCN9A</i> clinically available</div></li><li class="half_rhythm"><div>18 January 2007 (cd) Revision: mutations in <i>SCN9A</i> resulting in loss of function of sodium channel protein type 9 subunit alpha cause channelopathy-associated insensitivity to pain.</div></li><li class="half_rhythm"><div>5 May 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>2 August 2005 (fmh) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1163</span><span class="label">PMID: <a href="/pubmed/20301342" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301342</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/scn8a-ee/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/myo-dystonia/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1163&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1163/?report=reader">PubReader</a></li><li><a href="/books/NBK1163/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1163" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1163" style="display:none" title="Cite this Page"><div class="bk_tt">Hisama FM, Dib-Hajj SD, Waxman SG. SCN9A-Related Inherited Erythromelalgia. 2006 May 6 [Updated 2013 Aug 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1163/pdf/Bookshelf_NBK1163.pdf">PDF version of this page</a> (549K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#etha.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#etha.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#etha.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#etha.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#etha.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#etha.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#etha.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#etha.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#etha.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#etha.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#etha.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6335[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SCN9A</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1163+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1497578" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1497578" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1497578" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1497578" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26920677" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.</a><span class="source">[Brain. 2016]</span><div class="brieflinkpop offscreen_noflow">Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">McDonnell A, Schulman B, Ali Z, Dib-Hajj SD, Brock F, Cobain S, Mainka T, Vollert J, Tarabar S, Waxman SG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Brain. 2016 Apr; 139(Pt 4):1052-65. Epub 2016 Feb 26.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30416015" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series.</a><span class="source">[J Pediatr. 2019]</span><div class="brieflinkpop offscreen_noflow">Pediatric Erythromelalgia and SCN9A Mutations: Systematic Review and Single-Center Case Series.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Arthur L, Keen K, Verriotis M, Peters J, Kelly A, Howard RF, Dib-Hajj SD, Waxman SG, Walker SM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Pediatr. 2019 Mar; 206:217-224.e9. Epub 2018 Nov 9.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28990532" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.</a><span class="source">[Curr Mol Med. 2017]</span><div class="brieflinkpop offscreen_noflow">A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wu B, Zhang Y, Tang H, Yang M, Long H, Shi G, Tang J, Shi X. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Mol Med. 2017; 17(6):450-457. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27639908" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Erythromelalgia: Diagnosis and therapeutic approach].</a><span class="source">[Rev Med Interne. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Erythromelalgia: Diagnosis and therapeutic approach].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Miranda S, Le Besnerais M, Langlois V, Benhamou Y, Lévesque H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Rev Med Interne. 2017 Mar; 38(3):176-180. Epub 2016 Sep 14.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301342" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301342" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04135075f66d18aa0496c9">SCN9A-Related Inherited Erythromelalgia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">SCN9A-Related Inherited Erythromelalgia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:56:32-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A507FE040A3610000000003DC0160&amp;ncbi_session=CE8A507FE0413501_0988SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1163%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1163&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1163/&amp;ncbi_pagename=SCN9A-Related Inherited Erythromelalgia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A507FE0413501_0988SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>